ADX-077 Sales Forecast, and Market Size Analysis - 2034

Key Factors Driving ADX-077 Growth

1. Targets the rapidly expanding obesity treatment market

ADX-077 is being developed for obesity, one of the fastest-growing therapeutic areas globally. According to the World Health Organization (WHO), more than 1 billion people worldwide were living with obesity in 2022, including approximately 650 million adults, highlighting the substantial long-term demand for innovative therapies. If ADX-077 demonstrates clinically meaningful weight loss and a favorable safety profile, it could address a very large commercial opportunity.

2. Novel extrahepatic siRNA platform may provide differentiation

Unlike first-generation RNAi medicines that primarily target the liver, ADX-077 is part of ADARx's extrahepatic RNA delivery platform, designed to deliver siRNA beyond hepatocytes. This technology could enable therapeutic modulation of obesity-relevant targets that are inaccessible to conventional liver-directed GalNAc-siRNA therapies, representing a potentially important scientific and commercial differentiator.

3. Leverages ADARx's validated RNA interference technology

ADARx has advanced multiple RNAi candidates into clinical development, including Onvuzosiran (ADX-324) for hereditary angioedema and Agazisiran (ADX-038) for complement-mediated diseases. The progress of these programs validates the company's proprietary RNA chemistry and delivery platform, reducing technology risk for earlier pipeline assets such as ADX-077. In May 2025, ADARx also entered a multi-target collaboration with AbbVie, further supporting external confidence in its RNAi platform.

4. Potential for differentiated efficacy and convenient dosing

Although ADARx has not disclosed ADX-077's molecular target, long-acting siRNA therapeutics generally have the potential to produce durable target suppression with infrequent dosing compared with daily oral therapies. If ADX-077 achieves sustained efficacy with an extended dosing interval while maintaining acceptable tolerability, it could improve patient adherence and become competitive within the obesity treatment landscape. This advantage, however, remains to be demonstrated clinically.

5. Significant lifecycle expansion opportunities

Obesity is closely associated with type 2 diabetes, cardiovascular disease, metabolic dysfunction-associated steatohepatitis (MASH), chronic kidney disease, and obstructive sleep apnea. Successful development in obesity could create opportunities for expansion into these cardiometabolic indications, substantially increasing the therapy's long-term commercial potential. However, no such expansion plans have yet been publicly announced by ADARx.

ADX-077 Recent Developments

ADX 077 is an early stage, extra hepatic obesity siRNA, positioned conceptually in the GLP 1/anti obesity competitive landscape but mechanistically differentiated by RNAi and non hepatic targeting; however, it is still preclinical with limited public technical detail.

"ADX-077 Sales Forecast, and Market Size Analysis - 2034" report provides comprehensive insights of ADX-077 for potential indication like Metabolic disorders and Obesity in the 7MM. A detailed picture of ADX-077's existing usage in anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 -2034 is provided in this report along with a detailed description of the ADX-077 for potential indications. The ADX-077 market report provides insights about ADX-077's sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current ADX-077 performance, future market assessments inclusive of the ADX-077 market forecast analysis for potential indications in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of ADX-077 sales forecasts, along with factors driving its market.

ADX-077 Drug Summary

ADX-077 is an investigational RNA interference (RNAi) therapeutic being developed by ADARx Pharmaceuticals for the treatment of obesity. The candidate is designed using the company's proprietary RNAi platform to silence an undisclosed extrahepatic target involved in metabolic regulation, with the goal of improving energy balance and promoting sustained weight reduction. Unlike ADARx's liver-directed RNAi programs, ADX-077 is engineered for extrahepatic delivery, expanding the potential application of RNAi therapeutics to tissues beyond the liver. As a discovery-stage program, ADX-077 is currently undergoing preclinical optimization to evaluate its pharmacology, safety, and efficacy before advancement into clinical trials. The program represents ADARx's strategy to develop next-generation RNAi medicines for metabolic diseases by leveraging targeted gene silencing to achieve durable therapeutic effects with infrequent dosing. The report provides ADX-077's sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the ADX-077 Market Report

The report provides insights into:

• A comprehensive product overview including the ADX-077 MoA, description, dosage and administration, research and development activities in potential indication like Metabolic disorders and Obesity.
• Elaborated details on ADX-077 regulatory milestones and other development activities have been provided in ADX-077 market report.
• The report also highlights ADX-077's cost estimates and regional variations, reported and estimated sales performance, research and development activities in potential indications across the United States, Europe, and Japan.
• The ADX-077 market report also covers the patents information, generic entry and impact on cost cut.
• The ADX-077 market report contains current and forecasted ADX-077 sales for potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The ADX-077 market report also features the SWOT analysis with analyst views for ADX-077 in potential indications.

Methodology:

The ADX-077 market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

ADX-077 Analytical Perspective by DelveInsight

• In-depth ADX-077 Market Assessment

This ADX-077 sales market forecast report provides a detailed market assessment of ADX-077 for potential indication like Metabolic disorders and Obesity in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted ADX-077 sales data uptil 2034.

• ADX-077 Clinical Assessment

The ADX-077 market report provides the clinical trials information of ADX-077 for potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

ADX-077 Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

ADX-077 Market Potential & Revenue Forecast

• Projected market size for the ADX-077 and its key indications
• Estimated ADX-077 sales potential (ADX-077 peak sales forecasts)
• ADX-077 Pricing strategies and reimbursement landscape

ADX-077 Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• ADX-077 Market positioning compared to existing treatments
• ADX-077 Strengths & weaknesses relative to competitors

ADX-077 Regulatory & Commercial Milestones

• ADX-077 Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

ADX-077 Clinical Differentiation

• ADX-077 Efficacy & safety advantages over existing drugs
• ADX-077 Unique selling points

ADX-077 Market Report Highlights

• In the coming years, the ADX-077 market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The ADX-077 companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence ADX-077's dominance.
• Other emerging products for Metabolic disorders and Obesity are expected to give tough market competition to ADX-077 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of ADX-077 in potential indications.
• Analyse ADX-077 cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted ADX-077 sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of ADX-077 in potential indications.

Key Questions:

• What is the class of therapy, route of administration and mechanism of action of ADX-077? How strong is ADX-077's clinical and commercial performance?
• What is ADX-077's clinical trial status in each individual indications such as Metabolic disorders and Obesity and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the ADX-077 Manufacturers?
• What are the key designations that have been granted to ADX-077 for potential indications? How are they going to impact ADX-077's penetration in various geographies?
• What is the current and forecasted ADX-077 market scenario for potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of ADX-077 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to ADX-077 for potential indications?
• Which are the late-stage emerging therapies under development for the treatment of potential indications?
• How cost-effective is ADX-077? What is the duration of therapy and what are the geographical variations in cost per patient?